A frequent challenge for drug developers is how to target drugs – especially cancer drug, which aim to kill their target cells – to the right cell population. But researchers at Johns Hopkins University have turned this problem on its ear: Instead of delivering drugs specifically to cancer cells, they have developed a way to make cancer cells activate prodrugs through use of molecular switches.